Komei Tanaka1, Richard M Wilson1, Eric E Essick1, Jennifer L Duffen1, Philipp E Scherer1, Noriyuki Ouchi1, Flora Sam2. 1. From the Whitaker Cardiovascular Institute (K.T., R.M.W., E.E.E., J.L.D., N.O., F.S.) and Cardiovascular Section and Evans Department of Medicine (F.S.), Boston University School of Medicine, MA; and Touchstone Diabetes Center, Departments of Internal Medicine and Cell Biology, University of Texas Southwestern Medical Center, Dallas (P.E.S.). 2. From the Whitaker Cardiovascular Institute (K.T., R.M.W., E.E.E., J.L.D., N.O., F.S.) and Cardiovascular Section and Evans Department of Medicine (F.S.), Boston University School of Medicine, MA; and Touchstone Diabetes Center, Departments of Internal Medicine and Cell Biology, University of Texas Southwestern Medical Center, Dallas (P.E.S.). flora.sam@bmc.org.
Abstract
BACKGROUND: Despite the increasing prevalence of heart failure with preserved ejection fraction (HFpEF) in humans, there remains no therapeutic options for HFpEF. Adiponectin, an adipocyte-derived cytokine, exerts cardioprotective actions, and its deficiency is implicated in the development of hypertension and HF with reduced ejection fraction. Similarly, adiponectin deficiency in HFpEF exacerbates left ventricular hypertrophy, diastolic dysfunction, and HF. However, the therapeutic effects of adiponectin in HFpEF remain unknown. We sought to test the hypothesis that chronic adiponectin overexpression protects against the progression of HF in a murine model of HFpEF. METHODS AND RESULTS: Adiponectin transgenic and wild-type mice underwent uninephrectomy, a continuous saline or d-aldosterone infusion and given 1.0% sodium chloride drinking water for 4 weeks. Aldosterone-infused wild-type mice developed HFpEF with hypertension, left ventricular hypertrophy, and diastolic dysfunction. Aldosterone infusion increased myocardial oxidative stress and decreased sarcoplasmic reticulum Ca(2+)-ATPase protein expression in HFpEF. Although total phospholamban protein expression was unchanged, there was a decreased expression of protein kinase A-dependent phospholamban phosphorylation at Ser16 and CaMKII (Ca(2+)/calmodulin-dependent protein kinase II)-dependent phospholamban phosphorylation at Thr17. Adiponectin overexpression in aldosterone-infused mice ameliorated left ventricular hypertrophy, diastolic dysfunction, lung congestion, and myocardial oxidative stress without affecting blood pressure and left ventricular EF. This improvement in diastolic dysfunction parameters in aldosterone-infused adiponectin transgenic mice was accompanied by the preserved protein expression of protein kinase A-dependent phosphorylation of phospholamban at Ser16. Adiponectin replacement prevented the progression of aldosterone-induced HFpEF, independent of blood pressure, by improving diastolic dysfunction and by modulating cardiac hypertrophy. CONCLUSIONS: These findings suggest that adiponectin may have therapeutic effects in patients with HFpEF.
BACKGROUND: Despite the increasing prevalence of heart failure with preserved ejection fraction (HFpEF) in humans, there remains no therapeutic options for HFpEF. Adiponectin, an adipocyte-derived cytokine, exerts cardioprotective actions, and its deficiency is implicated in the development of hypertension and HF with reduced ejection fraction. Similarly, adiponectin deficiency in HFpEF exacerbates left ventricular hypertrophy, diastolic dysfunction, and HF. However, the therapeutic effects of adiponectin in HFpEF remain unknown. We sought to test the hypothesis that chronic adiponectin overexpression protects against the progression of HF in a murine model of HFpEF. METHODS AND RESULTS:Adiponectintransgenic and wild-type mice underwent uninephrectomy, a continuous saline or d-aldosterone infusion and given 1.0% sodium chloride drinking water for 4 weeks. Aldosterone-infused wild-type mice developed HFpEF with hypertension, left ventricular hypertrophy, and diastolic dysfunction. Aldosterone infusion increased myocardial oxidative stress and decreased sarcoplasmic reticulum Ca(2+)-ATPase protein expression in HFpEF. Although total phospholamban protein expression was unchanged, there was a decreased expression of protein kinase A-dependent phospholamban phosphorylation at Ser16 and CaMKII (Ca(2+)/calmodulin-dependent protein kinase II)-dependent phospholamban phosphorylation at Thr17. Adiponectin overexpression in aldosterone-infused mice ameliorated left ventricular hypertrophy, diastolic dysfunction, lung congestion, and myocardial oxidative stress without affecting blood pressure and left ventricular EF. This improvement in diastolic dysfunction parameters in aldosterone-infused adiponectintransgenic mice was accompanied by the preserved protein expression of protein kinase A-dependent phosphorylation of phospholamban at Ser16. Adiponectin replacement prevented the progression of aldosterone-induced HFpEF, independent of blood pressure, by improving diastolic dysfunction and by modulating cardiac hypertrophy. CONCLUSIONS: These findings suggest that adiponectin may have therapeutic effects in patients with HFpEF.
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff Journal: Circulation Date: 2013-06-05 Impact factor: 29.690
Authors: K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 2000-06 Impact factor: 8.311
Authors: Terry P Combs; Utpal B Pajvani; Anders H Berg; Ying Lin; Linda A Jelicks; Mathieu Laplante; Andrea R Nawrocki; Michael W Rajala; Albert F Parlow; Laurelle Cheeseboro; Yang-Yang Ding; Robert G Russell; Dirk Lindemann; Adam Hartley; Glynn R C Baker; Silvana Obici; Yves Deshaies; Marian Ludgate; Luciano Rossetti; Philipp E Scherer Journal: Endocrinology Date: 2003-10-23 Impact factor: 4.736
Authors: M Ehrhart-Bornstein; V Lamounier-Zepter; A Schraven; J Langenbach; H S Willenberg; A Barthel; H Hauner; S M McCann; W A Scherbaum; S R Bornstein Journal: Proc Natl Acad Sci U S A Date: 2003-11-12 Impact factor: 11.205
Authors: Wenning Qin; Amy E Rudolph; Brian R Bond; Ricardo Rocha; Eric A G Blomme; Joseph J Goellner; John W Funder; Ellen G McMahon Journal: Circ Res Date: 2003-06-05 Impact factor: 17.367
Authors: Vishal N Rao; Di Zhao; Matthew A Allison; Eliseo Guallar; Kavita Sharma; Michael H Criqui; Mary Cushman; Roger S Blumenthal; Erin D Michos Journal: JACC Heart Fail Date: 2018-10-10 Impact factor: 12.035
Authors: María Valero-Muñoz; Shanpeng Li; Richard M Wilson; Maarten Hulsmans; Tamar Aprahamian; José J Fuster; Matthias Nahrendorf; Philipp E Scherer; Flora Sam Journal: Circ Heart Fail Date: 2016-01 Impact factor: 8.790
Authors: Maria Valero-Munoz; Shanpeng Li; Richard M Wilson; Batbold Boldbaatar; Marc Iglarz; Flora Sam Journal: Circ Heart Fail Date: 2016-11 Impact factor: 8.790
Authors: María Valero-Muñoz; Albin Oh; Elizabeth Faudoa; Rosa Bretón-Romero; Fatima El Adili; Andreea Bujor; Flora Sam Journal: Circ Heart Fail Date: 2021-08-19 Impact factor: 10.447
Authors: Komei Tanaka; María Valero-Muñoz; Richard M Wilson; Eric E Essick; Conor T Fowler; Kazuto Nakamura; Maurice van den Hoff; Noriyuki Ouchi; Flora Sam Journal: JACC Basic Transl Sci Date: 2016-06-27
Authors: Hany M El-Bassossy; Wafaa S Al-Thubiani; Ahmed A Elberry; Mohammad I Mujallid; Salah A Ghareib; Ahmad S Azhar; Zainy M Banjar; Malcolm L Watson Journal: PLoS One Date: 2017-12-05 Impact factor: 3.240